Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy

Michela Milani1,2, Andrea Annoni1, Sara Bartolaccini1, Mauro Biffi1, Fabio Russo1, Tiziano Di Tomaso1, Andrea Raimondi3, Johannes Lengler4, Michael C Holmes5, Friedrich Scheiflinger4, Angelo Lombardo1,2, Alessio Cantore1,† & Luigi Naldini1,2,*,†

Abstract

Lentiviral vectors (LV) are powerful and versatile vehicles for gene therapy. However, their complex biological composition challenges large-scale manufacturing and raises concerns for in vivo applications, because particle components and contaminants may trigger immune responses. Here, we show that producer cell-derived polymorphic class-I major histocompatibility complexes (MHC-I) are incorporated into the LV surface and trigger allogeneic T-cell responses. By disrupting the beta-2 microglobulin gene in producer cells, we obtained MHC-free LV with substantially reduced immunogenicity. We introduce this targeted editing into a novel stable LV packaging cell line, carrying single-copy inducible vector components, which can be reproducibly converted into high-yield LV producers upon site-specific integration of the LV genome of interest. These LV efficiently transfer genes into relevant targets and are more resistant to complement-mediated inactivation, because of reduced content of the vesicular stomatitis virus envelope glycoprotein G compared to vectors produced by transient transfection. Altogether, these advances support scalable manufacturing of alloantigen-free LV with higher purity and increased complement resistance that are better suited for in vivo gene therapy.

Keywords gene therapy; hemophilia; lentiviral vectors; MHC-I; stable producer cell line

Introduction

Gene therapy has recently shown remarkable progress in clinical trials and promises to provide effective treatment for several genetic and acquired diseases (Naldini, 2015). Underlying this success is the development of improved gene transfer vectors (Kay, 2011; Mingozzi & High, 2011; Nathwani et al, 2014). Among them, lentiviral vectors (LV) are emerging as versatile vehicles of relatively large capacity for stable transgene integration in the genome of target cells. LV are currently exploited both for ex vivo gene therapy, in which target cells (such as hematopoietic stem/progenitor cells, HSPC or T cells) are harvested from the patient, transduced, and then re-infused, and for in vivo gene therapy, in which LV are directly injected into the patient, either into the bloodstream or in situ, such as in the brain (Palfi et al, 2014). Whereas several ongoing clinical trials support the efficacy and safety of LV for ex vivo gene therapy (Cartier et al, 2009; Cavazzana-Calvo et al, 2010; Aiuti et al, 2013; Biffi et al, 2013; Maude et al, 2014), in vivo liver-directed gene therapy with LV remains more challenging. Indeed, LV particles undergo a complex assembly with the outer envelope deriving from the membrane of packaging cells, thus comprising an array of proteins beside the viral antigens that may act as immune triggers upon recognition and phagocytosis by professional antigen presenting cells (APC; Annoni et al, 2013). Moreover, current manufacturing of LV mostly relies on transient plasmid co-transfection, which is labor-intensive and poorly amenable to scale-up and standardization, and leads to substantial amount of impurities, including residual plasmid DNA, which may further aggravate APC activation. In addition, the reported instability of vesicular stomatitis virus glycoprotein G (VSV.G)-pseudotyped LV in human serum remains a concern for in vivo administration (DePolo et al, 2000; Croyle et al, 2004; Trobridge et al, 2010; Hwang & Schaffer, 2013). We have previously reported that, upon
intravenous administration, LV allow stable gene transfer to the liver, provided that transgene expression is stringently targeted to hepatocytes, and have shown dose-dependent therapeutic efficacy in a mouse and a canine model of hemophilia B, a coagulation disorder due to mutations in the factor IX (FIX)-encoding gene (Brown et al., 2006; Matrai et al., 2011; Cantore et al., 2012, 2015). Despite the therapeutic potential, some hurdles remain to be addressed before considering clinical translation of in vivo LV administration, such as the manufacturing of sufficiently large, consistent, and highly purified batches for in vivo delivery, the vector stability in the circulation, and the risk of acute toxicity and immunogenicity triggered by particle components or contaminants. Here, we describe an inducible scalable packaging cell line, which supports consistent generation of high-yield producers of LV of interest by a targeted integration strategy. LV produced by these cells achieve equivalent levels of gene transfer in the liver and are stable upon concentration and purification as LV produced by conventional transfection, but are more resistant to inactivation in human sera and lack plasmid DNA contaminants. Moreover, by further editing the genome of LV producer cells, we modified the protein composition of their plasma membrane and in turn of the LV envelope and obtained novel LV with enhanced capacity to escape immune recognition, which are better suited for in vivo applications.

Results

Reproducible generation of LV producer cell lines by targeted integration

In order to avoid toxicity due to stable expression of viral components, we took advantage of a regulated, tetracycline (Tet)-dependent system, in which a Tet-regulated transcriptional repressor (Tet-R) binds to DNA sequences included in a promoter and represses transcription by steric hindrance (Yao et al., 1998; Jones et al., 2005). Upon addition of doxycycline (dox), Tet-R is released, allowing transcription. To generate LV producer cell lines, we thus started from a 293 cell line stably expressing Tet-R. We then step-wise transfected the plasmids expressing third-generation LV components, human immunodeficiency virus type 1 (HIV) Rev, Gag/Pol, and the VSV.G pseudotype (Dull et al., 1998), under the control of Tet-regulated promoters and coupled with antibiotic resistance cassettes (Fig 1A and B). We first introduced Rev, showed inducible Rev expression in 32/33 clones analyzed (Appendix Fig S1A), then pooled >4,000 clones, and stably transfected Gag/Pol. We then screened clones for inducible LV particle production (Appendix Fig S1B), pooled the six highest expressing clones, and stably transfected VSV.G. We confirmed inducible Rev and VSV.G expression (Appendix Fig S1C) and pooled the highest expressing clones to obtain the packaging cell line. This line yielded 66 ± 14 ng of HIV Gag p24/ml after dox addition, with >500-fold induction over a very low basal level (Fig 1C and Appendix Fig S1B), a productivity that, although in the lower range of that obtained by transient transfection, prompted us to continue development of this cell line. We found one copy of Rev, Gag, and VSV.G DNA per genome in the packaging cell line (Fig 1D), suggesting that integration site selection rather than copy accumulation played a role in the higher expression. We thus adopted site-specific integration as an efficient and reproducible means to introduce a full-length, self-inactivating (SIN)-LV genome transfer construct (Zufferey et al., 1998; Follenzi et al., 2000), and convert the packaging into a producer cell line (see Fig 1B). We targeted the adeno-associated virus site 1 (AAVS1), previously described as permissive to high-level stable expression and tolerant to integration, exploiting site-specific endonucleases and homology-directed repair (Lombardo et al., 2011). We included a GFP selector preceded by a splice acceptor site and a sequence encoding the self-cleaving 2A peptide after the LV 3’ long terminal repeat (Figs 1E and EV1A). Because integration occurs in the first intron of the PPP1R12C gene,
GFP expression originates from the endogenous promoter (Lombardo et al., 2011), allowing selection of targeted cells. We performed three independent targeted integrations (T.I.) of LV constructs expressing GFP or human FIX, either wild-type (wt) or a codon-optimized hyper-functional version (FIX-Padua; Fig EV1A; Cantore et al., 2015), by transiently co-delivering zinc-finger nucleases (ZFN) targeting AAVS1 and the plasmid donor DNA. We achieved between 2 and 5% of GFP-positive cells, then enriched the GFP-positive cells by fluorescence-activated cell sorting (FACS), and obtained bulk and several single-cell-derived clones (n = 51) for each targeting (Fig EV1B). All clones analyzed (43/43 that grew well in culture among the 51 clones) were GFP positive, with some variation in mean fluorescence intensity (MFI) which was lower in those targeting in which GFP expression relied on splicing and 2A-mediated protein release, as expected (Fig EV1C). All clones except for one showed one copy of Rev, Gag, and VSV.G DNA per genome and no integration of ZFN DNA (Fig EV1D and E); the majority of the clones (44/51) presented the two expected AAVS1-LV genome junctions by PCR (Fig 1F), 34 clones (67%) had one LV copy per cell, 10 (20%) had two, four (8%) > 2, and three (6%) had none (Fig 1G and H). Together, these data show a high rate of monallelic on-target integration of this strategy, as previously reported for different purposes (Lombardo et al., 2011).

**Robust and scalable LV production by stable producer cell lines**

We measured infectious titer, physical particles, and specific infectivity of LV-containing supernatant of dox-induced bulk-sorted positive populations and single-cell clones, selected for robust growth rate, for the three T.I. experiments. At peak production, 3 days after induction (Fig EV2A and B), we found on average 1.5 × 10^6 transducing units (TU)/ml, 56 ng/ml p24 equivalents, 3 × 10^4 TU/ng p24, reaching up to 4.4 × 10^6 TU/ml, 222 ng p24/ml, and 8 × 10^4 TU/ng p24 (Fig 2A). The infectivity of cell-line-produced LV was in the lower-bound range of that obtained for LV produced by transient transfection in our standard conditions. We compared the LV output of several different inductions of the bulk-sorted LV-GFP producer cell line over the course of 1 year and observed that productivity is maintained also after a freeze/thaw cycle and even without antibiotic selective pressure (Fig 2B). Lentiviral vectors production was scaled in cell factories up to 6 liters with similar or higher output in the collected conditioned medium than measured in small-scale experiments (Table 1), and this medium was processed by our previously reported two-step chromatography purification (Biffi et al., 2013), giving the expected final yield of vector. Specific infectivity was maintained both throughout the purification process and after concentration by ultracentrifugation (Fig EV2C). Concentrated LV was stable at –80°C after 10 months of storage (Fig EV2D). Overall, these data indicate comparable stability of LV particles produced by the cell line or by transient transfection. We found undetectable titer (< 100 TU/ml) and 120 pg p24/ml in medium collected from the LV-GFP producer cell line in the absence of dox (see also Appendix Fig S1B), suggesting that the low amount of LV particles produced are not infectious, possibly because the low levels of Rev in the non-induced condition limit nuclear exports of full-length LV genome for encapsidation. These data are consistent with the reported low leakiness of the Tet-R system and support the long-term stability observed for the cell line, which may be protected from the toxicity of viral proteins and from LV superinfection in the non-induced state. Overall, these data show that single-copy integration into AAVS1 mediates robust transcription of the LV genome and the generation of highly infectious vector particles.

We then transduced human cord blood-derived HSPC with concentrated LV produced by the two most productive clones of the LV-GFP producer cell line, or by transient transfection. We observed a LV dose-dependent increase in the percentage of transduced cells and vector copies per diploid genome (vector copy number, VCN), reaching up to 45% GFP-positive and 1.9 VCN in the cultured cells, 70% GFP-positive cells and 2.8 VCN in CFC assay, at the highest multiplicity of infection (MOI) of the cell-line produced LV, and a two- to fivefold lower dose–response than observed for transient transfection LV (Fig 2C–F). The percentage of erythroid (CD235a-positive) and myeloid (CD33-positive) cells among the total CFC did not change significantly among the different transfections (Fig EV3A–C). The lower transduction efficiency of cell-line-derived than transient transfection-derived LV at matched MOI likely reflects the lower specific infectivity of the former vector. However, the cell-line-produced LV still allowed reaching clinically relevant VCN in the HSPC (Aiuti et al., 2013; Biffi et al., 2013). We also transduced activated primary human T cells and achieved >90% transduction and VCN > 5 at the highest MOI of LVs produced by either method (Fig 2G and H). We did not observe any skewing in the CD4/CD8.
Figure 2.
The table shows infectious titer, physical parameters, and specific infectivity of (i) LV-containing conditioned medium collected from LV-FIX-Padua producer cells 3 days after dox addition (initial material) and (ii) concentrated purified LV formulated in saline solution at 5% dimethyl sulfoxide (final product), according to our previously reported process (Biffi et al., 2013; Cantore et al., 2015). Note that the yield of the process is in line with results previously reported for LV produced by conventional transient transfection (Aiuti et al., 2013; Biffi et al., 2013) and that the recovery in specific infectivity is 100%.

**Table 1. Purification of cell line-produced LV.**

| Initial | Final | Yield |
|---------|-------|-------|
| Titer TU/ml | 4.2 × 10^5 | 1.1 × 10^4 |
| Particles ng p24/ml | 396 | 1.1 × 10^3 |
| Infectivity TU/ng p24 | 1.1 × 10^2 | 6000 |
| Volume ml | 6.00 | 2.5 × 10^10 |
| Total TU | 2.4 × 10^6 |
| ng p24 | 7.2 × 10^9 |

We also determined LV inactivation in sera of different species and found that, while mouse sera did not significantly inactivate LV, dog sera showed a slightly stronger inactivation than human serum and the dose-dependent LV inactivation profile was overlapping for monkey and human sera (Fig 3G), suggesting that monkey models should appropriately predict the human setting, concerning complement-mediated LV inactivation. Overall, these data show that LV inactivation in human serum is dependent on the LV concentration and the amount of VSV.G on the viral particles and it could be potentially rescued by using anti-complement antibody. However, VSV.G-low LV, such as those produced by the stable cell line, are more resistant to complement-mediated inactivation in human serum (Fig 3B). Because it has been shown that a major determinant of LV inactivation is VSV.G, we hypothesized that the increased resistance of cell line-produced LV was due to a reduced content of VSV.G on the envelope of these LV. To test this hypothesis, we produced LV with decreasing amounts of the VSV.G-expressing construct by transient transfection and measured the content of VSV.G on LV particles by immune electron microscopy. The VSV.G content per virion of cell line LV was on average 35% less than that of LV produced by transient transfection with standard amount of VSV.G plasmid (Fig 3E and F). LV with decreasing VSV.G content showed increased resistance to inactivation in human sera and LV produced by transfection with the lowest amount of VSV.G plasmid showed the most similar dose inactivation profile to the cell line-produced LV in this assay (see Fig 3B).
Figure 3.
serum. To further investigate whether additional factors are responsible for the higher resistance of the cell line-produced LV to complement-mediated inactivation in human serum, we measured the expression of CD35, CD46, CD55, and CD59 complement regulatory proteins (Garcia et al., 2016) in the packaging cell line and in 293T cells used for transient transfection. All these proteins except for CD59 were expressed in both cell types with slightly higher expression of CD46 and CD59 in the former cells (Fig EV4), which might contribute in part to the increased resistance of cell line LV to complement-mediated inactivation.

**Reduced immune activation by MHC-free LV**

MHC-I molecules from the producer cell surface become incorporated in the vector particles, as shown by Western blot of LV lysates and electron microscopy of LV particles immunostained with anti-MHC-I antibodies (Fig 4A–C). Because MHC-I molecules are highly polymorphic and immunogenic across different individuals (Shiina et al., 2009), we generated producer cells devoid of surface-exposed MHC-I by permanently disrupting the gene encoding for beta-2 microglobulin (B2M), required for the expression of MHC-I molecules on the cell membrane (Adiko et al., 2015). We transiently delivered the Cas9 nuclease (Hsu et al., 2014) and single-guide RNA (sgRNA) targeting the first exon or the start codon of the B2M gene, to the LV packaging cell line or 293T cells, generally used to produce LV by transient transfection. Up to 44% of the cells lost B2M expression and, as a consequence, MHC-I expression on their membrane (Figs 4D and EV5A–C). These results were confirmed at the genetic level, showing up to 35% of B2M alleles bearing indels (Fig EV5B and C). We then enriched for B2M-negative or B2M-positive cells to near purity (> 95%) by FACS. We found no significant differences in infectious titer, particles, and infectivity of LV produced by B2M-negative or B2M-positive sorted cells (Fig EV5D–F). Western blot and electron microscopy on LV produced by B2M-negative cells (MHC-free LV) showed lack of MHC-I antigen (see Fig 4A–C). The absence of MHC on LV did not affect the level of incorporation of VSV.G (see Fig 4C). FIX output and liver VCN were overlapping in hemophilia B mice treated with LV-FIX-Padua produced in B2M-positive or B2M-negative cells by transient transfection, or by the most productive clone of the B2M-negative producer cell line, further confirming comparable liver gene transfer by LV produced by either cells and methods (Fig 4E and F). MHC-free LV were more resistant to antibody-dependent complement-mediated inactivation than their MHC-bearing counterparts in sera obtained from allo-immunized individuals, such as poly-transfused patients, which contained antibodies against the MHC specificities of 293T cells (Fig 4G). We also observed increased stability of MHC-free LV in human sera when comparing LV pseudotyped with the baculovirus GP64 envelope protein, although these pseudotypes were per se more resistant to complement-mediated inactivation than VSV.G pseudotypes, as previously shown (Fig 4H; Schauer et al., 2004). We then observed that human primary T cells were significantly less activated when co-cultured with autologous monocytes previously exposed to MHC-free LV than conventional MHC-bearing LV particles, both when testing LV particles pseudotyped with VSV.G or with GP64, although the latter pseudotype is known to show tropism restriction against hematopoietic lineage cells (Fig 4I and J; Schauer et al., 2004). These data show that APC exposed to conventional LV present allo-antigens derived from the vector particles that can trigger alloimmune immune responses. Importantly, these responses were substantially decreased by using MHC-free LV particles, independently on the vector pseudotype. Overall, these results show that MHC-I-negative cells, generated by genetic inactivation of B2M, produce MHC-free LV that have the same infectivity but lower immunogenicity than conventional LV.

**Discussion**

Here, we report the generation of LV with modified surface, achieved by changing the protein composition of the producer cell
Figure 4.
plasma membrane through genome editing. These LV lack polymorphic MHC molecules that may otherwise trigger allogeic adaptive immune responses. We noted that human primary T cells are activated by autologous monocytes exposed to LV, an effect significantly inhibited by using MHC-free LV, indicating productive presentation of LV-derived allo-MHC antigens. Because MHC molecules of producer cells are incorporated into LV, they might in turn be transferred to the plasma membrane of APC upon LV uptake, or their digested fragments might be presented on class-I and class-II MHC of the APC, thus eliciting an allo-reactive immune response, potentially leading to immune-mediated killing of the target cells shortly after transduction. Furthermore, antibodies against the MHC specificities of the producer cells inactivated LV particles. Such allo-antibodies can be found in patients frequently exposed to blood cell products and might compromise in vivo gene transfer and trigger cytotoxicity and phagocytosis of autologous cells shortly after in vivo or ex vivo transduction by LV. In contrast, MHC-free LV alleviate all these risks. Genetic inactivation of B2M in producer cells yielded LV with comparable transduction efficiency to their standard counterparts, in striking contrast to wt HIV, which instead was recently reported to require MHC-I for full-particle infectivity because of its association with the HIV envelope proteins (Serena et al., 2017). MHC-free LV are thus better suited for human gene therapy, because of reduced concerns for eliciting immune responses. These results represent a paradigm for further iteration of engineering producer cells to enhance the properties of advanced therapy medicinal products, a task made easy by current genome editing technology.

The improved LV were produced by standard transfection or exploiting novel stable inducible producer cell lines. Several inducible LV packaging cell lines have already been reported, but their reproducible conversion into producer cell lines has been challenging (Kafri et al., 1999; Farson et al., 2001; Brousseau et al., 2008; Stewart et al., 2009; Throm et al., 2009; Stornaiuolo et al., 2013). The LV genome has been introduced either by a viral vector, an approach, however unsuitable for SIN vectors, or by stable transfection, which may generate rearrangements and concatamers with low expression and sometimes inhibitory activity on packaging and titer. Here, we show that single-copy integration of a full-length packaging competent LV genome into a validated locus allows consistent generation of high-titer producer cell lines, overcoming the need to extensively characterize each new producer cell line for every LV of interest. Although the LV genome is constitutively expressed, its nuclear export and encapsidation are Rev-dependent, thus explaining the lack of detectable infectious LV in the medium of non-induced producers, which protects the cells by LV superinfection. The stability and scalability of these producer cells in culture also reflect the tight regulation of the toxic VSV.G protein. Further development may result in adaptation of these cells to grow in suspension and sustain expansion at industrial scales.

As ex vivo T-cell-based gene therapies progress to the market stage, the availability of scalable LV producer cell lines will meet the requirement for larger batch sizes and improved quality and standardization of the therapeutic product. In addition, consistent generation of new LV producers may help addressing the need for rapid development of patient-specific vectors expressing T-cell receptor genes that target tumor neo-antigens. Stable LV producer cell lines may be even more crucial to support the development of in vivo gene therapies. We show here that LV produced by our stable cell line are more resistant to complement-mediated inactivation in human sera, due, at least in part, to a reduced content of VSV.G. The classical complement activation pathway is triggered by clustering of antibody–antigen complexes on the target antigen; thus, we speculate that even a relatively small (35%) reduction in the density of VSV.G on the vector envelope can decrease immunoglobulin clustering, resulting in pronounced reduction of complement fixation on the LV particles. While the lower VSV.G content did not impair vector stability upon purification or the efficiency of liver gene transfer, it may explain the lower transduction efficiency of HSPC by the cell line-produced LV, compared to LV produced by transient transfection. LV lacking MHC-I and with low VSV.G content may thus be advantageous for in vivo delivery, not only because of the improved resistance to complement-mediated inactivation but also because they are likely to be less opsonized and inflammatory. Altogether, the advances described in this work, by decreasing LV immunogenicity and sensitivity to complement-mediated inactivation and supporting their scalable manufacturing, should improve the feasibility, safety, and efficacy of in vivo gene therapy with LV.

Materials and Methods

Experimental design

Sample size was chosen according to previous experience with experimental models and assays. No sample or animal was excluded from the analyses. Mice were randomly assigned to each experimental group. Investigators were not blinded.

Plasmid construction

The linearized HindIII pcDNA5/TO plasmid (Invitrogen) was ligated with HindIII Rev fragment of plasmid pK-Rev (Biffi et al., 2013), to obtain pY-Rev. The Mlu-NotI restriction fragment of pcDNA5/TO was inserted into Mlu-HindIII backbone of plasmid pCMV3.1—neomycin-containing plasmid. The resulting construct was digested with NosiI and BamHI and ligated with BamHI-NotI Gag/Pol fragment from pKLGag/Pol (Biffi et al., 2013) to obtain pY-Gag/Pol. The VSV.G fragment of plasmid pK.G (Biffi et al., 2013) was ligated with backbone of pcDNA5/TO using BamHI and NosiI restriction enzymes. The resulting plasmid was double-digested with HindIII-BamHI and subsequently ligated to the HindIII-BamHI puromycin fragment of pSV40-puro (Selexis) to obtain pY-VSV.G. The donor plasmid for the LV-GFP targeting (pLV-GFP) was generated by introducing the AAVS1 left and right homology arms into the NcoI site of pSV40-puro (Selexis) to obtain pY-VSV.G. The donor plasmid for the LV-FIX or LV-FIX-Padua targeting was obtained exchanging the PKG.GFP expression cassette of the LV-GFP donor plasmid with the ET.hFIX.142T expression cassette or ET.co-hFIX-Padua of pCCLsin.PPT.hPGK.GFP.wpre. The donor plasmid for the LV-FIX or LV-FIX-Padua targeting was obtained exchanging the PKG.GFP expression cassette of the LV-GFP donor plasmid with the ET.hFIX.142T expression cassette or ET.co-hFIX-Padua of pCCLsin.PPT.hPGK.GFP.wpre. The donor plasmid for the LV-FIX or LV-FIX-Padua targeting was obtained exchanging the PKG.GFP expression cassette of the LV-GFP donor plasmid with the ET.hFIX.142T expression cassette or ET.co-hFIX-Padua of pCCLsin.PPT.hPGK.GFP.wpre. The donor plasmid for the LV-FIX or LV-FIX-Padua targeting was obtained exchanging the PKG.GFP expression cassette of the LV-GFP donor plasmid with the ET.hFIX.142T expression cassette or ET.co-hFIX-Padua of pCCLsin.PPT.hPGK.GFP.wpre.
the CRISPR used to generate the sgRNA are as follows: B2M exon 1 (GAGTACGCGGACACAGCTAAGG), B2M start codon (GGCCACGG AGCGACATCTCGG).

Packaging cell line generation

At Baxter, 293 T-REx cells (Invitrogen) were cultivated in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) with 10% fetal calf serum (Invitrogen), and 5 mg/l blasticidin S (Invitrogen); 293 T-REx cells were transfected by electroporation using 5 µg of pY-Rev, following manufacturer’s instructions (PEQLAB, Microporator MP-100), selected in the presence of 5 mg/l blasticidin S and 50 mg/l hygromycin B (Invivogen); 293 T-REx Rev cells were then transfected as above with pY-Gag/Pol plasmid, selected in the presence of 5 mg/l blasticidin S, 50 mg/l hygromycin B, 2.5 mg/l Geneticin (Invitrogen) and were then transfected with pY-VSV.G plasmid as above and selected in the presence of 5 mg/l blasticidin S, 50 mg/l hygromycin B, 2.5 mg/l geneticin, 5 mg/l puromycin (Sigma) to generate the packaging cell line.

Site-specific integration and gene disruption

Targeted integration in AAVS1 was performed by calcium phosphate-mediated transient transfection of the indicated amount of the desired donor plasmid and the ZFN-expressing plasmid (Lombardo et al., 2011). Gene disruption was performed by calcium phosphate-mediated transient transfection of the indicated amount of the desired sgRNA-expressing plasmid and the Cas9-expressing plasmid.

LV production

VSV.G-pseudotyped third-generation self-inactivating (SIN) LV were produced by calcium phosphate transient transfection into 293T cells, or by LV packaging or producer cell lines. 293T cells were transfected with a solution containing a mix of the selected LV genome transfer plasmid, the packaging plasmids pMDLg/pRRE and pCMV.REV, pMD2.G or pBA-AcMNPV-gp64 (Schauber et al., 2004) and pAdVantage (Promega), as previously described (Cantore et al., 2015). Medium was changed 14–16 h after transfection and supernatant was collected 30 h after medium change. Alternatively, LV production was induced when LV producer or packaging cells were in a sub-confluent state, by replacing the culture medium with medium containing doxycycline (Sigma) 1 µg/ml and supernatant was collected 3 days after induciton. LV-containing supernatants were passed through a 0.22-µm filter (Millipore) and, when needed, transferred into sterile poliallomer tubes (Beckman) and centrifuged at 20,000 g for 120 min at 20°C (Beckman Optima XL-100K Ultra-centrifuge). LV pellet was dissolved in the appropriate volume of PBS to allow 500–1,000× concentration. LV purification from large-scale (6,000 ml) production was performed as described (Biffi et al., 2013; Cantore et al., 2015).

LV titration

For LV titration, 100,000 293T cells were transduced with serial LV dilutions in the presence of polybrene (8 µg/ml). For LV-GFP, cells were analyzed by flow cytometry 3–7 days after transduction and infectious titer, expressed as transducing unit ( TU/ml, was calculated using the formula TU/ml = (% GFP+ cells/100) *100,000/(1/dilution factor). For all other LV, genomic DNA (gDNA) was extracted 14 days after transduction, using Maxwell 16 Cell DNA Purification Kit (Promega), following manufacturer’s instructions. VCN was determined by quantitative PCR (qPCR) starting from 100 ng of template gDNA using primers (HIW fwd: 5′-TACTGACGCTTTCCGACC-3′; HIW rev: 5′-TCTGACGAGGAGGACTG-3′) and a probe (FAM 5′-ATCTCTCTCTTACGCT-3′) against the primer binding site region of LV. The amount of endogenous DNA was quantified by a primers/probe set against the human telomerase gene (Telo fwd: 5′-GCCACACCTGCTTTCCG-3′; Telo rev: 5′-GTTGAACCTCCTGAATTTATGCAA-3′; Telo probe: VIC 5′-TACGG ACCTCGAGTGCAACGGGT-3′ TAMRA). VCN was calculated by the formula = (ng LV/ng endogenous DNA)* number of LV integrations in the standard curve. The standard curve was generated, by using a CEM cell line stably carrying one vector integrant, which was previously determined by Southern blot and fluorescent in situ hybridization (FISH). All reactions were carried out in duplicate or triplicate in a ViiA7 Real Time PCR thermal cycler (Applied Biosystems). Each qPCR run carried an internal control generated by using a CEM cell line stably carrying four vector integrants, which were previously determined by Southern blot and FISH analysis. Infectious titer, expressed as TU/ml, was calculated using the formula TU/ml = (VCN*100,000/(1/dilution factor)). LV physical particles were measured by HIV-1 Gag p24 antigen immunocapture assay (Perkin Elmer) following manufacturer’s instructions. LV specific infectivity was calculated as the ratio between infectious titer and physical particles.

Cell cultures

293T, LV packaging and producer cell lines were maintained in Iscove’s modified Dulbecco’s medium (IMDM, Sigma) supplemented with 10% fetal bovine serum (FBS, Euroclone), 4 mM glutamine (Lonza), penicillin, and streptomycin 100 IU/ml (Lonza). Human cord blood-derived CD34-positive cells were purchased from Lonza and kept in culture at the concentration of 10⁶ cells/ml in Stem Spam SFEM (Stem Cell Technologies) supplemented with human cytokines purchased from PeproTech, thrombopoetin (TPO, 100 ng/ml), interleukin-6 (IL-6, 100 ng/ml), stem cell factor (SCF, 20 ng/ml), Flt3 ligand (FLT3L, 20 ng/ml) for at least 7 days, then cultured in IMDM supplemented with 10% FBS, 4 mM glutamine, penicillin, and streptomycin 100 IU/ml to prompt differentiation. The CFC assay was performed as described (Escobar et al., 2014). Human cord blood mononuclear cells enriched for CD3-positive T cells were kept in culture at a concentration of 10⁶ cells/ml in IMDM supplemented with interleukin 7 (5 ng/ml), interleukin 15 (5 ng/ml), 10% FBS, 4 mM glutamine, penicillin, and streptomycin 100 IU/ml. T lymphocytes were prestimulated in vitro with beads coated with anti-human CD3 and anti-human CD28 (3 beads/cell, Dynabeads human T-activator CD3/CD28, Invitrogen). Four days after transduction, beads were mechanically detached and removed using MagnaRack (Invitrogen). Primary human monocytes and lymphocytes were magnetically sorted (Miltenyi Biotec) fromuffy coats of healthy donors. All cells were maintained in a 5% CO₂ humidified
atmosphere at 37°C. All cell lines were routinely tested for mycoplasma contamination.

**AAVS1-LV junction detection**

The presence of junctions between the AAVS1 genomic locus and the 3` and 5` of the donor DNA construct was tested in gDNA extracted using Maxwell 16 Cell DNA Purification Kit (Promega) following manufacturer’s instructions. For the LV-GFP targeting in the AAVS1 site, we set a PCR (AmpliTaq Gold DNA polymerase system by Applied Biosystems) using primers for detecting the 5` junction (AAVS1 fw: 5`-AATCCTGCCCCTTAACGGCTGC-3`; ΔNef rv: 5`-CGAGCTCGTACCTTTAAGACC-3`) and for detecting the 3` junction (Gag fw: 5`-GAGTCTGGCTGAGAGACG-3`; AAVS1 rv: 5`-AAC GGGATGCAAGGGGAACG-3`). For LV-FIX or LV-FIX-Padua targeting in the AAVS1 site, we set a PCR using primers for detecting the 5` junction (AAVS1 fw: 5`-AATCCTGCCCCTTAACGGCTGC-3`; GFP rv: 5`-GCTTGGATGTTGCCGTCGC-3`) and for detecting the 3` junction (Gag fw: 5`-GAGTCTGGCTGAGAGACG-3`; AAVS1 rv: 5`-AA CGGGATGCAAGGGGAACG-3`). PCR products were analyzed on a 1% agarose gel.

**Mismatch-selective endonuclease assay**

The mismatch-selective endonuclease assay was used to measure the extent of mutations consequent to non-homologous end joining (NHEJ) at the Cas9 target sites, as described (Lombardo et al., 2011). PCR was performed using primers flanking the sgRNA binding site in the B2M gene (fw: 5`-TACAGACGACAAACTCACC CAGTC-3`; rv: 5`-AGAACCTTGAGAAGGAAGTGCAAG-3`). The PCR product was denatured, allowed to re-anneal, and digested with Surveyor nuclease assay (Transgenomic). Because this enzyme cuts DNA at sites of duplex distortions, the products of re-annealing between wild-type and mutant alleles (carrying mutations or deletions consequent to the nuclease activity) are specifically digested. The reaction products were separated on a Spreadex EL1200 Wide Mini gel (Elchrom Scientific), stained by ethidium bromide or GelRed (Biotium), and the intensity of the products of mismatch-selective endonuclease assay was measured using the ImageQuant TL 5 software. The ratio of the uncleaved parental fragment to the lower two migrating cleaved products was calculated using the formula (1-(parental fraction)^1/2) * 100.

**DNA copy determination in LV packaging and producer cells**

Rev, Gag, VSV.G DNA copies were determined by ddPCR on gDNA extracted using Maxwell 16 Cell DNA Purification Kit (Promega), starting from 5 to 20 ng of template gDNA and using primers/probe sets against the desired cDNA (Rev fw: 5`-CTTATTGACCTATCTGG GACG-3`; Rev rv: 5`-TAAAGCTCTGCTAAAGGGGTGT-3`; Rev probe: FAM 5`-TGGGAGCAGTTGCTTCTAGC-3`; Gag fw: 5`-ATCAAG CACGATCAGTAAATG-3`; Gag rv: 5`-CTTGGGTCTTCTCCTGCGGCG-3`; Gag probe: FAM 5`-TGAGATCTGCATGCGGGGACC-3`; VSV fw: 5`-CTTCCCTCCTGCTAAAGGTGT-3`; VSV rv: 5`-GAATCCTACCTGGGAATTGA GACA-3`; VSV probe: FAM 5`-TGAACATCTGAGCGGATGCC GAAGCA-3`). The amount of endogenous DNA was quantified by a primers/probe set against the human telomerase gene, as above. Since 200 ng of gDNA corresponds to 60,000 genomes, it was possible to calculate the number of LV DNA copies/diploid genomes.

**Human cell experiments**

HSPC and T lymphocytes transduction was performed at the indicated MOI (TU/cell). Purified CD14-positive monocytes (purity > 95%) were exposed to MHC-free or control MHC-bearing LV particles produced without vector genome (1 µg of HIV Gag p24/10^6 CD14-positive cells) for 16 h for VSV.G-pseudotyped LV, or spinoculated for 2 h at 1,100 g at 37°C, or left untreated as control. LV-exposed monocytes were washed three times and then co-cultured for 48 h with autologous purified T cells (purity > 95%) at 1:1 ratio in X-vivo-15 (Lonza) supplemented with 5% human serum, penicillin, and streptomycin 100 IU/ml. T cells secreting IFN-γ in response to autologous LV-exposed monocytes were enumerated by conventional elispot assay using purified anti-human IFN-γ (clone1-D1K, Mabtech) as capture and biotin-conjugated anti-human IFN-γ (clone7-B6-1, Mabtech) as detection antibodies. Spots were counted by ELLExpert Elispot reader and analyzed by Eli.Analyse software (A.EL.Vis). When comparing MHC-free or MHC-bearing LV in this assay, we produced both LV in parallel from B2M-MHC double-positive or double-negative cells sorted from the same population treated for B2M disruption (stable packaging cell line or 293T for use in transient transfection) in order to minimize variations not directly related to MHC content.

**Flow cytometry**

Flow cytometry analyses were performed using a FACS Canto analyzer (BD Biosciences), equipped with DIVA Software. Between 100,000 and 500,000 cells were harvested, washed with PBS or MACS buffer (PBS pH 7.2 0.5% BSA, 2 mM EDTA), treated with Fc Receptor-Block (Miltenyi Biotech) when antibody stained, and then resuspended in the buffer used for washing. Staining was performed in MACS buffer, incubating cells with antibodies (in the proportion indicated in the table below) for 20 minutes at 4°C in the dark. For vitality staining, 7-aminoactinomycin D (7AAD, Sigma) was used. Anti-murine IgG beads were used for single-staining controls (BD Biosciences). Rainbow beads (BD Biosciences) were used to calibrate the instrument detectors, for consistent MFI measurement, for analysis performed at different times.
Alloantigen-free lentiviral vectors  Michela Milani et al

Mice experiments

Founder C57BL/6 F9 knockout mice were originally obtained from the laboratory of Dr. Inder Verma at the Salk Institute (Wang et al., 1997). All the mice were maintained in specific pathogen-free conditions. Vector administration was carried out in adult (7- to 10-week-old) male or female mice by tail vein injections. When both male and female were used in the same experiment, they were equally distributed between different treatment groups. Mice were bled from the retro-orbital plexus using capillary tubes, and blood was collected into 0.38% sodium citrate buffer, pH 7.4. Mice were anesthetized with tribromoethanol (Avertin) and euthanized by CO2 inhalation at the expected time points. All animal procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee.

Antigen Fluorochrome Clone Company Dilution

| Antigen | Fluorochrome | Clone | Company           | Dilution |
|---------|--------------|-------|-------------------|----------|
| CD33    | BV421        | WM53  | BD Biosciences    | 1:20     |
| CD235a  | APC          | REA175| Miltenyi Biotec   | 1:20     |
| CD34    | VioBlue      | AC136 | Miltenyi Biotec   | 1:20     |
| CD3     | PE-Cy7       | HI133 | BioLegend         | 1:50     |
| CD4     | Pacific Blue | RPA-T4| BioLegend         | 1:50     |
| CD8     | APC-Cy7      | SK1   | BD Biosciences    | 1:33     |
| CD35    | PE           | E11   | BD Biosciences    | 1:50     |
| CD46    | PE           | 8E2   | eBioscience       | 1:20     |
| CD55    | PE           | JS11  | BioLegend         | 1:33     |
| CD59    | PE           | p2B2  | BioLegend         | 1:33     |
| B2M     | PE           | 2M2   | BioLegend         | 1:20     |
| MHC-I   | APC          | W6/32 | Santa Cruz Biotech| 1:10     |

Electron microscopy

Few microliters of concentrated LV batches were absorbed on glow-discharged carbon-coated formvar copper grids and fixed for 20 min with 8% paraformaldehyde in PBS. After several washes in 50 mM glycine in PBS, grids were blocked in 1% BSA in PBS and incubated with primary antibodies diluted in blocking buffer for 30–90 min (Anti-VSV.G, KeraFAST, 1:50, Anti-MHC-I, Santa Cruz Biotech, 1:20). After several washes in 0.1% BSA in PBS, samples were incubated for 30 min with Protein A-gold (5 or 10 nm), fixed with 1% glutaraldehyde, stained with 2% uranyl acetate, or a mix of 0.4% uranyl acetate and 1.8% methyl-cellulose, then air-dried. Grids were observed with a Zeiss LEO 512 transmission electron microscope. Images were acquired with a 2 k x 2 k bottom-mounted slow-scan Proscan camera controlled by EvisionPro 3.2 software. For quantification of labeling density, random images of viral particles were taken at nominal magnification of 16k and gold particles associated to virions were manually counted using ImageJ. Virions were defined based on expected size (approximately 120 nm) and an electron-dense core.

Western blot

Total proteins in LV batches were extracted with membrane-protein lysis buffer (150 mM Tris–HCl, 150 mM NaCl, EDTA 5 mM, 1% deoxycholate, 0.1% SDS, 1% Triton X-100) supplemented with PIC (Protease Inhibitor Cocktail, Roche). Samples were resuspended in the lysis solution and incubated at 4°C for 10 min. Lysates were assayed for protein concentration using Bradford assay (Bio-Rad). Twenty micrograms of proteins was run on SDS–PAGE under reducing conditions. For immunoblotting, proteins were transferred to polyvinylidene difluoride (PVDF) membranes using iBlot Gel Transfer stacks (Novex), incubated with the specific antibody followed by peroxidase-conjugated secondary antibodies (ECL Mouse or Rabbit IgG GE Healthcare), and detected using chemiluminescent reagents (ECL, GE Healthcare) and exposure to autoradiography films. The following antibodies were used: rabbit monoclonal anti-human MHC-I (OriGene Technologies, 1:1,000 in TBS, Tween-20 0.1%, skim milk powder 5%) and mouse monoclonal anti-Gag p24 (NIH control), and the mixture was incubated at 37°C for 1 h. Following incubation, medium was added to the reaction and then serially diluted and used to transduce 293T cells for end-point infectious titer determination, as described (Cantore et al., 2015). The titer value was divided by the titer determined for the LV mixed with medium (the no-serum control) and reported as the percentage of recovery of titer compared to this control. When comparing MHC-free or MHC-bearing LV in this assay, we produced both LV in parallel by transient transfection in 293-MHC double-positive or double-negative cells sorted from the same population treated for B2M disruption in order to minimize variations not directly related to MHC content. Eculizumab (commercial name Soliris, produced byAlexion Pharmaceuticals) was obtained from leftovers of patients’ doses at the San Raffaele Hospital and added to the LV:serum mix at the indicated concentration. Mouse serum was purchased (Sigma), dog serum was kindly provided by Dr. Timothy Nichols (University of North Carolina), and monkey serum was kindly provided by Dr. Eduard Ayuso (University of Nantes).

Enzyme-linked immunosorbent assay (ELISA)

The concentration of human FIX was determined in mouse plasma by ELISA specific for human FIX antigen (Asserachrom IX:Ag, Stago) following manufacturer’s instructions. Absorbance of each sample was determined at a spectrophotometer, using a Multiskan GO microplate reader (Thermo Fisher Scientific) and normalized to antigen standard curves.

LV inactivation assay

Human serum samples were obtained from 12 healthy donors from San Raffaele Hospital or purchased (Sigma). To test MHC-free LV, human serum samples were obtained from four allo-immunized patients from San Raffaele Hospital, upon obtaining informed consent, according to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Sera were thawed, and half of each serum sample was heated at 56°C for 1 h to inactivate the complement. LV were diluted in Iscove’s modified Dulbecco’s medium (IMDM, Sigma) supplemented with 10% fetal bovine serum (FBS, Euroclone). Twenty microliters of LV was diluted 1:5 into fresh or heat-inactivated serum (or IMDM 10% FBS as the no-serum control), and the mixture was incubated at 37°C for 1 h. Following incubation, medium was added to the reaction and then serially diluted and used to transduce 293T cells for end-point infectious titer determination, as described (Cantore et al., 2015). The titer value was divided by the titer determined for the LV mixed with medium (the no-serum control) and reported as the percentage of recovery of titer compared to this control. When comparing MHC-free or MHC-bearing LV in this assay, we produced both LV in parallel by transient transfection in 293-MHC double-positive or double-negative cells sorted from the same population treated for B2M disruption in order to minimize variations not directly related to MHC content. Eculizumab (commercial name Soliris, produced byAlexion Pharmaceuticals) was obtained from leftovers of patients’ doses at the San Raffaele Hospital and added to the LV:serum mix at the indicated concentration. Mouse serum was purchased (Sigma), dog serum was kindly provided by Dr. Timothy Nichols (University of North Carolina), and monkey serum was kindly provided by Dr. Eduard Ayuso (University of Nantes).
AIDS reagent program #3537, 1:1,000 in TBS, Tween-20 0.1%, skim milk powder 5%).

Lentiviral vectors packaging cells (10^5) were lysed for 5 min at 95°C in NuPAGE®LDS sample buffer (Thermo Fisher Scientific) and run on SDS–PAGE and then blotted on nitrocel lullose membrane (Thermo Fisher Scientific). After blocking the membrane for half an hour in 5% dry milk powder, Rev and VSV.G proteins were stained by the primary antibodies against HIV-1 Rev 1:200 (Santa Cruz Biotechnology) and anti-VSV.G 1:1,000 (Abcam), respectively, and the secondary HRP-labeled anti-mouse IgG1 antibody 1:50,000 (GE Healthcare), all diluted in TBS Tween-20 0.1%. As internal control, the beta-actin housekeeping gene was stained by anti-beta-actin antibodies 1:3,300 (Novus Biologicals) and HRP-labeled anti-rabbit IgG1 1:50,000 (Thermo Fisher Scientific).

**Vector Copy Number (VCN) determination in transduced cells**

For human HSPC experiments, DNA was extracted from both liquid culture and colony-forming cell (CFC) assay, using DNAeasy Blood & Tissue Kit (Qiagen) following manufacturer’s instructions. For human T-cell experiments, gDNA was extracted using Maxwell 16 Cell DNA Purification Kit (Promega). For mice experiments, DNA was extracted from whole liver samples using Maxwell 16 Tissue DNA Purification Kit (Promega). Vector Copy Number was determined in HSPC and T cells as previously described (Escobar et al., 2014). Vector Copy Number in murine DNA was determined by droplet digital (dd)PCR, starting from 5 to 20 ng of template gDNA using primers (HIV fw: 5'-TACTGACGCTCTCGACC-3'; HIV rv: 5'-TCTCGAGCGAAGACTCG-3') and a probe (FAM 5'-ATCTCTCTCC TTCTAGCTC-3') against the primer binding site region of LV. The amount of endogenous murine DNA was quantified by a primers/probe set against the murine *sema3a* gene (Sema3A fw: 5'-ACCGATTTCCAGATGATTCGCG-3'; Sema3A rv: 5'-TCTATATTATGCGACTGC TGGTGG-3'; Sema3A probe: HEX 5'-AGAGGCCGTCTCGACGC TG-3' BHQ1). The PCR was performed with each primer (900 nM) and the probe (250 nM) following manufacturer's instructions (Bio-Rad), read with QX200 reader and analyzed with QuantaSoft software (Bio-Rad).

**Statistical analysis**

Statistical analyses were performed upon consulting with professional statisticians. When normality assumptions were not met, nonparametric statistical tests were performed. Mann–Whitney or Kruskal–Wallis tests were performed when comparing two or more experimental groups, respectively. For paired observations, Wilcoxon matched pairs test was performed.

**Expanded View** for this article is available online.

**Acknowledgements**

We thank S. Marktel (San Raffaele Hematology and Bone Marrow Transplantation Unit) for serum samples from allo-immunized patients; T. Plati and A. Migliara for help with some experiments; MolMed S.p.A. for large-scale production using the LV producer cell line; A. Nonis, A. Pramov, and C. Di Serio for statistical consulting; T. Liu and R. Peters (Bioverativ) and all other members of the Naldini, Lombardo, and Gentner laboratories for helpful discussions. We thank the ALEMBC facility at the San Raffaele Scientific Institute for help with electron microscopy analysis. M.M. conducted this study as partial fulfillment of her International Ph.D. Course in Molecular Medicine at San Raffaele University, Milan. This work was supported by Telethon (SR-Tiget Core Grant 2011-2016), and Bioverativ sponsored research agreement.

**Author contributions**

MM designed and performed experiments, analyzed and interpreted data, and contributed to writing the manuscript. AA designed and performed experiments and interpreted data concerning T-cell responses. SB, MB, FR, and TDT performed experiments and analyzed data. AR performed electron microscopy experiments. JL performed experiments and analyzed data concerning the original LV packaging cell-line generation. FS supervised JL research. MCH provided reagents. AL provided intellectual input and reagents, interpreted data on genome editing experiments, and edited the manuscript. LN and AC designed and supervised research, interpreted data, and wrote the manuscript. LN provided overall coordination and financial support.

**Conflict of interest**

L.N. is inventor on patents on LV technology and microRNA-regulated LV (gene vector, WO2007000668). A.C., A.L., and L.N. are inventors on a filed patent on MHC-negative LV producer cells. These patents are owned by Telethon Foundation and San Raffaele Scientific Institute. The LV and reagents described in this manuscript are available to interested scientists upon signing a MTA with standard provisions. There are some restrictions concerning research involving LV for the gene therapy of hemophilia, except for research aimed at reproducing the findings reported in this manuscript, according to a collaboration agreement between Telethon Foundation, the San Raffaele Scientific Institute, and Bioverativ.

**The paper explained**

**Problem**

Lentiviral vectors (LV) are attractive vehicles for gene therapy. However, their in vivo administration remains particularly challenging, as it requires high quantity and quality of vector and raises concerns for the activation of innate and adaptive immune responses, which may be detrimental for both the safety and efficacy of the therapy. Moreover, carryover of allogeneic histocompatibility complexes on LV particles from the human vector producer cells may contribute to these immune responses.

**Results**

Here, we generate stable cell lines, which support scalable and consistent production of LV that are capable of efficient liver gene transfer and are more resistant to complement-mediated inactivation in human sera. Moreover, by genetically inactivating the beta-2 microglobulin gene in LV producer cells, we obtain LV lacking class-I major histocompatibility complex on their surface, which maintain gene transfer capacity and escape immune recognition by human T cells.

**Impact**

The advances described in this work, by supporting scalable manufacturing of LV and decreasing their immunogenicity and sensitivity to complement-mediated inactivation, should facilitate their application to in vivo gene therapy for hemophilia and other diseases. Moreover, we show that targeted genome editing of producer cells can be applied to improve the properties of gene therapy vectors, an approach which may have broad application in molecular medicine.
References

Adiko AC, Babdor J, Gutierrez-Martinez E, Guermonprez P, Saveanu L (2015) Intracellular transport routes for MHC I and their relevance for antigen cross-presentation. *Front Immunol* 6: 335

Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalèse MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castelli MC et al (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science* 341: 1233151

Amabile A, Migliara A, Capasso P, Biffi M, Cittaro D, Naldini L, Lombardo A (2016) Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. *Cell* 167: 219–232.e214

Annoni A, Goudy K, Akbarpour M, Naldini L, Roncarolo MG (2013) Immune responses in liver-directed lentiviral gene therapy. *Transl Res* 161: 230–240

Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science* 341: 1233158

Broussau S, Jabbour N, Lachapelle G, Durocher Y, Tom R, Transfiguracion J, Gilbert R, Massie B (2008) Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. *Mol Ther* 16: 500–507

Brown BD, Venneri MA, Zingale A, Sergi S, Sergi L, Naldini L (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. *Nat Med* 12: 585–591

Cantore A, Nair N, Della Valle P, Di Matteo M, Matrai J, Sanvito F, Brombin C, Di Serio C, D’Angelo A, Chuaah M et al (2012) Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. *Blood* 120: 4517–4520

Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D et al (2015) Liver-directed lentiviral gene therapy in a dog model of hemophilia B. *Sci Transl Med* 7: 277ra228

Cartier N, Haein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 326: 818–823

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K et al (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. *Nature* 467: 318–322

Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP (2004) PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. *J Virol* 78: 912–921

DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, Dubensky TW Jr (2000) VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. *Mol Ther* 2: 218–222

Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivious vector with a conditional packaging system. *J Virol* 72: 8463–8471

Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrato ML, Kajaste-Rudnitski A, Bondonza A, Gentner B, De Palma M, Mazzieri R et al (2014) Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. *Sci Transl Med* 6: 217ra213

Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio A, Naldini L (2001) A new-generation stable inducible packaging cell line for lentiviral vectors. *Hum Gene Ther* 12: 981–997

Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. *Nat Genet* 25: 217–222

Garcia BL, Zwarthoff SA, Roijakkers SH, Geisbrecht BV (2016) Novel evasion mechanisms of the classical complement pathway. *J Immunol* 197: 2051–2060

Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 157: 1262–1278

Hwang BY, Schaffer DV (2013) Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. *Gene Ther* 20: 807–815

Jones J, Nivitchanyong T, Giblin C, Ciccarrone V, Judd D, Gorfien S, Krag SS, Betenbaugh MJ (2005) Optimization of tetracycline-responsive recombinant protein production and effect on cell growth and ER stress in mammalian cells. *Biotechnol Bioeng* 91: 722–732

Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM (1999) A packaging cell line for lentivirus vectors. *J Virol* 73: 576–584

Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. *Nat Rev Genet* 12: 316–328

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med* 368: 2169–2181

Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, Colombo DF, Neri M, Magnani Z, Cantore A, Lo Riso P et al (2011) Site-specific integration and tailoring of cassette design for sustainable gene transfer. *Nat Methods* 8: 861–869

Matrai J, Cantore A, Bartholomae CC, Annoni A, Wang W, Acosta-Sanchez A, Samara-Kuko E, De Waele L, Ma L, Genovese P et al (2011) Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. *Hepatology* 53: 1696–1707

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chea W, Gonzalez VE, Zheng Z, Lacey SF et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* 371: 1507–1517

Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. *Nat Rev Genet* 12: 341–355

Naldini L (2015) Gene therapy returns to centre stage. *Nature* 526: 351–360

Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheritier E, Patel N, Raj D et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. *N Engl J Med* 371: 1994–2004

Pafi S, Guruchaga JM, Ralph LS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deleey S et al (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. *Lancet* 383: 1138–1146

Rother RP, Rollins SA, Mojczik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. *Nat Biotechnol* 25: 1256–1264

Schauber-Plewa C, Simmons A, Tuerk MJ, Pacheco CD, Veres G (2005) Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. *Gene Ther* 12: 266–275

Schauber-Plewa C, Simmons A, Tuerk MJ, Pacheco CD, Veres G (2005) Complement regulatory proteins are incorporated into lentiviral vectors
and protect particles against complement inactivation. *Gene Ther* 12: 238–245

Serena M, Parolini F, Biswas P, Sironi F, Blanco Miranda A, Zoratti E, Scupoli MT, Ziglio S, Valenzuela-Fernandez A, Gibellini D et al (2017) HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity. *Sci Rep* 7: 40037

Shiina T, Hosomichi K, Inoko H, Kulski JK (2009) The HLA genomic loci map: expression, interaction, diversity and disease. *J Hum Genet* 54: 15–39

Stewart HJ, Leroux-Carlucci MA, Sion CJ, Mitrophanous KA, Radcliffe PA (2009) Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. *Gene Ther* 16: 805–814

Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F, Mavilio F, Bordignon C, Rizzardi GP, Bovolenta C (2013) RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. *Hum Gene Ther Methods* 24: 228–240

Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M, Deravin SS, Moayeni M, Malech HL, Sorrentino BP et al (2009) Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. *Blood* 113: 5104–5110

Trobridge GD, Wu RA, Hansen M, Ironside C, Watts KL, Olsen P, Beard BC, Kiem HP (2010) Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. *Mol Ther* 18: 725–733

Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM (1997) A factor IX-deficient mouse model for hemophilia B gene therapy. *Proc Natl Acad Sci USA* 94: 11563–11566

Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E (1998) Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. *Hum Gene Ther* 9: 1999–1950

Zanta-Boussif MA, Charrier S, Brice-Ouzet A, Martin S, Opolon P, Thrasher AJ, Hope TJ, Galy A (2009) Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. *Gene Ther* 16: 605–619

Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiraz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J Virol* 72: 9873–9880

Zufferey R, Donello JE, Trono D, Hope TJ (1999) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. *J Virol* 73: 2886–2892

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.